Insiders Trades
Centene Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 11 Aug 2025.
Centene Corp: what insiders have been doing
Centene Corp, classified in the Healthcare & Pharma sector, is a listed company based in St. Louis, United States, founded in 1984. Its insiders report their share dealings to SEC (Form 4). The last twelve months, up to 18 October 2026, brought 55 filings signed by 17 insiders.
Only sales appear on the open market, 4 sales in all totalling €7.0M, filed by 2 insiders. No amount is published for 1 filing, which the totals therefore leave out. The largest single trade was a sale of €3.2M by Koster Christopher, published on 27 August 2026, equal to 0.012% of the market capitalisation.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Compared with its exchange (5,810 companies, median 19 filings), a count of 55 filings is above the norm. Our records for Centene Corp go back to 2016, with 16 purchases and 32 sales on the open market in total. The 10-K for the year ended 31 December 2025 shows 194.78 bn USD of revenue and -6.67 bn USD of net income.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
398
Thresholds
n/a
Buy Volume
€8M
16 ops. · all time
Sell Volume
€21M
32 ops. · all time
Who traded when
BuySaleBurdick Kenneth A2 sales
Christopher Koster2 sales
London Sarah2 buys
Theodore R. Samuels II2 buys
Asher Andrew Lynn1 buy
Blume Jessica L.1 buy
+3 other insiders
Since the insiders bought
- +156.3%Entry US$26.17 · Close at T+365 US$67.07
- +135.9%Entry US$25.79 · Close at T+365 US$60.84
- +6.6%Entry US$73.08 · Close at T+365 US$77.91
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Centene Corp Buy (bullish), based on 18 analysts. Average price target: US$71.78.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 19,421 of 24,148 companies
30.6
score / 100
Value48
Quality13
FCF yld13%
Earn yld-20%
EV/EBITDA·
ROE-20%
Gross mgn7.1%
Net mgn-3.4%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$70.16
Analyst consensus
18 analystsBuy
US$56.00Target US$71.78(+2%)US$85.00
Income statement
RevenueUS$194.8B
Gross profitUS$13.9B7% margin
EBITDA-US$4.8B-2% margin
Net income-US$6.7B-2.8% margin
Valuation
PER (forward)13.1x
P/Book1.5x
Beta1.13
Balance sheet & cash
Market capUS$34.7B
Total debtUS$18.2B
Free Cash FlowUS$4.3B
Debt / Equity71%
Profitability & ownership
ROE-20.4%
ROA2.5%
% insiders0.4%
% institutions101.7%
Last declaration on 15 October 2026
Declarations398 total
7,130 shares@ US$70.160.0014% mcap100.0% of flowCommon StockSEC:0001071739-26-000188:0
482 shares0Common StockSEC:0001071739-26-000184:0
603 shares0Common StockSEC:0001071739-26-000183:0
864 shares0Common StockSEC:0001071739-26-000181:0
583 shares0Common StockSEC:0001071739-26-000180:0
583 shares0Common StockSEC:0001071739-26-000182:0
1,092 shares@ US$69.410.0002% mcap100.0% of flowCommon StockSEC:0001071739-26-000174:0
56,500 shares@ US$66.900.012% mcap17.6% of flowCommon StockSEC:0001071739-26-000169:0
43,600 shares@ US$65.000.0090% mcap9.4% of flowCommonSEC144:0001959173-26-006473
56,500 shares@ US$66.900.012% mcap17.6% of flowCommonSEC144:0001959173-26-006459
47,603 shares@ US$65.360.0100% mcap14.6% of flowCommon StockSEC:0001071739-26-000167:0
47,603 shares@ US$65.35850.0100% mcap14.6% of flowCommonSEC144:0001959173-26-006161
100,000 shares@ US$68.15180.022% mcap22.9% of flowCommonSEC144:0001959173-26-005683
2,771 shares0Common StockSEC:0001071739-26-000158:0
3,155 shares0Common StockSEC:0001071739-26-000146:0
562 sharesCommon StockSEC:0001071739-26-000140:0
833 sharesCommon StockSEC:0001071739-26-000141:0
465 sharesCommon StockSEC:0001071739-26-000142:0
581 sharesCommon StockSEC:0001071739-26-000143:0
61 sharesCommon StockSEC:0001071739-26-000144:0
483 sharesCommon StockSEC:0001071739-26-000129:0
80,000 sharesCommon StockSEC:0001071739-26-000127:0
80,000 shares@ US$64.55280.015% mcap17.3% of flowCommonSEC144:0001959173-26-004540
3,992 shares0Common StockSEC:0001071739-26-000110:0
3,992 shares0Common StockSEC:0001071739-26-000109:0
25 of 398 declarations
About Centene Corp
Centene Corp. (ticker: CNC) is a major U.S. managed healthcare company listed on the NYSE in the United States, with headquarters in St. Louis, Missouri. The company was founded in 1984 as a nonprofit Medicaid plan under the name Family Hospital Physician Associates (FHPA) in Milwaukee, then adopted the Centene name in 1997 and relocated its corporate headquarters to St. Louis. Over time, Centene has evolved from a local safety-net insurer into a national managed-care platform built around a community-based operating model. ([centene.com](https://www.centene.com/who-we-are/history.html?utm_source=openai))
Centene’s core business is organized around three main lines: Medicaid, Medicare, and the Health Insurance Marketplace. It also reports an “Other” segment for residual activities, although management has signaled a sharper strategic focus on its core platforms. The company describes itself as the largest Medicaid managed care organization in the U.S. and a long-standing leader in the Marketplace. Its product set includes government-sponsored health plans, Medicare Advantage coverage, Medicare Prescription Drug Plans (PDP), and related care-management and health-services solutions. ([centene.com](https://www.centene.com/who-we-are/history.html?utm_source=openai))
Read moreShow less
From a competitive standpoint, Centene’s scale and local-market approach are central differentiators. The company operates across all 50 states and states that it serves more than one in 15 people nationwide. Its business model is highly regulated and operationally complex, but it benefits from a large membership base and a diversified footprint across state Medicaid programs and ACA Marketplace plans. Recent disclosures, however, highlight a more challenging operating backdrop, particularly in Medicaid and Marketplace, with margin pressure and ongoing portfolio cleanup. ([centene.com](https://www.centene.com/who-we-are/history.html?utm_source=openai))
Recent developments are important for investors. On February 6, 2026, Centene reported full-year 2025 results and announced 2026 guidance, including adjusted diluted EPS guidance above $3.00, while emphasizing actions aimed at restoring Marketplace profitability and stabilizing the Medicaid trajectory. In December 2025, the company also signed a definitive agreement to divest the remaining Magellan Health businesses, underscoring a broader strategic simplification effort. In its first-quarter 2026 update, Centene continued to focus on margin improvement, cost discipline, and execution across its core segments. ([investors.centene.com](https://investors.centene.com/2026-02-06-CENTENE-CORPORATION-REPORTS-2025-RESULTS-AND-ANNOUNCES-2026-GUIDANCE?utm_source=openai))
For French-speaking investors, Centene is best viewed as a managed-care and government-program healthcare operator with strong U.S. scale, a defensive end-market profile, and meaningful sensitivity to reimbursement trends, utilization patterns, and regulatory changes in Medicaid and the ACA Marketplace. ([centene.com](https://www.centene.com/content/dam/centenedotcom/investor_docs/CNC-2026-Proxy-2025-Annual-Report.pdf?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
